Pharmacotherapy of helminth infection

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 3, 2009, Pages 435-451

  Van Den Enden, Erwin ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Anthelmintics; Cestoda; Nematoda; Therapy; Trematoda

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ARTEMISININ DERIVATIVE; BITHIONOL; CARBAMAZEPINE; CIMETIDINE; DEXAMETHASONE; DIAMIDINE DERIVATIVE; DIETHYLCARBAMAZINE; DOXYCYCLINE; FLUBENDAZOLE; IVERMECTIN; LEVAMISOLE; MEBENDAZOLE; METRIFONATE; MOXIDECTIN; NICLOSAMIDE; NIRIDAZOLE; NITAZOXANIDE; OXAMNIQUINE; OXANTEL; OZ 78; PF 1002 A; PHENYTOIN; PIPERAZINE; PLACEBO; PRAZIQUANTEL; PYRANTEL EMBONATE; TIABENDAZOLE; TRICLABENDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGITATION; AGRANULOCYTOSIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANCYLOSTOMA DUODENALE; ANGIONEUROTIC EDEMA; ANOREXIA; ARACHNOIDITIS; ARTHRALGIA; ASCARIASIS; BIRTH DEFECT; BLINDNESS; BRAIN EDEMA; CERCARIAL DERMATITIS; CESTODIASIS; CLINICAL TRIAL; CLONORCHIASIS; COCHRANE LIBRARY; CONFUSION; CONVULSION; CRYPTOSPORIDIOSIS; CUTANEOUS LARVA MIGRANS; CYSTICERCOSIS; DERMATITIS; DIARRHEA; DIZZINESS; DRACUNCULIASIS; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHINOCOCCOSIS; ECHINOCOCCUS MULTILOCULARIS; ELECTROCARDIOGRAM; EMBRYOTOXICITY; ENTEROBIASIS; EOSINOPHILIA; EVENING DOSAGE; EYE INFLAMMATION; FACE EDEMA; FASCIOLIASIS; FATIGUE; FEVER; FILARIASIS; GASTROINTESTINAL SYMPTOM; GIARDIA LAMBLIA; GIARDIASIS; GNATHOSTOMIASIS; HALLUCINATION; HEADACHE; HELMINTHIASIS; HOOKWORM INFECTION; HUMAN; HYDROCEPHALUS; HYMENOLEPIASIS; HYPERSENSITIVITY REACTION; INFESTATION; INFLAMMATION; INTESTINE HEMANGIOMA; INTRAHEPATIC CHOLESTASIS; KERATITIS; LEUKOCYTOSIS; LEUKOPENIA; LIMBITIS; LIVER CAPILLARIASIS; LOIASIS; LYMPH VESSEL; LYMPHADENITIS; LYMPHANGITIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; MEDLINE; MESH HEADING; MORNING DOSAGE; MYALGIA; NAUSEA; NEMATODIASIS; NEUROCYSTICERCOSIS; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OESOPHAGOSTOMIASIS; OLIGOSPERMIA; ONCHOCERCIASIS; OPTIC NERVE INFLAMMATION; PAPULAR RASH; PARAGONIMIASIS; PARAGONOMIASIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PROTEINURIA; PRURITUS; PSYCHOPATHY; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; RETINA MACULA DEGENERATION; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SPERMATOGENESIS; STEVENS JOHNSON SYNDROME; STRONGYLOIDIASIS; TACHYCARDIA; TAENIASIS; TERATOGENESIS; THERAPY EFFECT; THROMBOCYTOPENIA; TINNITUS; TOXOCARIASIS; TREATMENT RESPONSE; TREMATODIASIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; TRICHURIASIS; UNSPECIFIED SIDE EFFECT; URTICARIA; UVEITIS; VASCULITIS; VISCERAL LARVA MIGRANS SYNDROME; VISUAL IMPAIRMENT; VOMITING; WORLD HEALTH ORGANIZATION;

ANTHELMINTICS; CESTODE INFECTIONS; HUMANS; NEMATODE INFECTIONS; TREMATODE INFECTIONS;

EID: 65649114316     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902722463     Document Type: Review

References (219)

1. Renoux G. The general immunopharmacology of levamisole. Drugs 1980;20:89-99
2. Albonico M, Bickle Q, Ramsan M, et al. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003;81:343-352 (Pubitemid 36644260)
3. Grover JK, Vats V, Uppal G, Yadav S. Anthelmintics: a review. Trop Gastroenterol 2001;22:180-189
4. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008;299:1937-48 •• An excellent, comprehensive, systematic review of ascariasis, trichuriasis and hookworm disease. (Pubitemid 351574924)
5. Albonico M, Bickle Q, Haji HJ, et al. Evaluation of the efficacy of pyrantel-oxantel for the treatment of soil-transmitted nematode infections. Trans R Soc Trop Med Hyg 2002;96:685-690
6. St Georgiev V. Chemotherapy of enterobiasis (oxyuriasis). Expert Opin Pharmacother 2001;2:267-275 (Pubitemid 32427730)
7. Reynoldson JA, Behnke JM, Pallant LJ, et al. Failure of pyrantel in treatment of human hookworm infections (Ancylostoma duodenale) in the Kimberley region of north west Australia. Acta Trop 1997;68:301-312 (Pubitemid 28041317)
8. Krepel HP, Haring T, Baeta S, Polderman AM. Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole. Trans R Soc Trop Med Hyg 1993;87:87-89 (Pubitemid 23093075)
9. Bloom A. Studies of the mode of action of metrifonate and DDVP in schistosomes - cholinesterase activity and the hepatic shift. Acta Pharmacol Toxicol (Copenh) 1981;49(Suppl 5):109-113
10. O'Leary KA, Tracy JW. Schistosoma mansoni: glutathione S-transferase-catalyzed detoxication of dichlorvos. Exp Parasitol 1991;72:355-361
11. Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008;16(3):CD000053
12. Bassiouny HK, Soliman NK, el Daly SM, Badr NM. Human fascioliasis in Egypt: effect of infection and efficacy of bithionol treatment. J Trop Med Hyg 1991;94:333-337
13. Mavrova AT, Anichina KK, Vuchev DI, et al. Antihelminthic activity of some newly synthesized 5(6)-(un)substituted-1H-benzimidazol-2- ylthioacetylpiperazine derivatives. Eur J Med Chem 2006;41:1412-1420
14. Martin RJ, Robertson AP, Bjorn H. Target sites of anthelmintics. Parasitology 1997;114(Suppl):S111-24 (Pubitemid 27397869)
15. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002;346:1212-1220
16. Cioli D, Pica-Mattoccia L, Archer S. Drug resistance in schistosomes. Parasitol Today 1993;9:162-166 (Pubitemid 23126427)
17. Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis 2007;20:524-32 • A review of several aspects of common and rarer intestinal cestode infections in humans.
18. Varma TK, Shinghal TN, Saxena M, Ahluwalia SS. Studies on the comparative efficacy of mebendazole, flubendazole and niclosamide against human tapeworm infections. Indian J Public Health 1990;34:163-168
19. Wulff C, Haeberlein S, Haas W. Cream formulations protecting against cercarial dermatitis by Trichobilharzia. Parasitol Res 2007;101:91-97 (Pubitemid 46669252)
20. McMahon JE. A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium. Ann Trop Med Parasitol 1983;77:139-142
21. El Beheiry AH, Kamel MN, Gad A. Niridazole and fertility in bilharzial men. Arch Androl 1982;8:297-300
22. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990;6:112-115 (Pubitemid 20131119)
23. Hodgkinson JE, Clark HJ, Kaplan RM, et al. The role of polymorphisms at beta tubulin isotype 1 codons 167 and 200 in benzimidazole resistance in cyathostomins. Int J Parasitol 2008;38:1149-1160
24. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006;367:1521-32 • An up-to-date review of important soil-transmitted helminth infections.
25. Bhargava A, Jukes M, Lambo J, et al. Anthelmintic treatment improves the hemoglobin and serum ferritin concentrations of Tanzanian schoolchildren. Food Nutr Bull 2003;24:332-342 (Pubitemid 38193180)
26. Stephenson LS, Latham MC, Kurz KM, et al. Treatment with a single dose of albendazole improves growth of Kenyan schoolchildren with hookworm, Trichuris trichiura, and Ascaris lumbricoides infections. Am J Trop Med Hyg 1989;41:78-87 (Pubitemid 19212250)
27. de Silva NR. Impact of mass chemotherapy on the morbidity due to soil-transmitted nematodes. Acta Trop 2003;86:197-214 (Pubitemid 36561368)
28. Beasley NM, Tomkins AM, Hall A, et al. The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Trop Med Int Health 1999;4:744-750
29. Gyorkos TW, Larocque R, Casapia M, Gotuzzo E. Lack of risk of adverse birth outcomes after deworming in pregnant women. Pediatr Infect Dis J 2006;25:791-794 (Pubitemid 44325780)
30. de Silva NR, Sirisena JL, Gunasekera DP, et al. Effect of mebendazole therapy during pregnancy on birth outcome. Lancet 1999;353:1145-1149 (Pubitemid 29155208)
31. Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans R Soc Trop Med Hyg 2001;95:72-73 (Pubitemid 34202230)
32. Montresor A, Awasthi S, Crompton DW. Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop 2003;86:223-232 (Pubitemid 36561370)
33. Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982;76:114-118
34. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003;86:141-159
35. Nontasut P, Singhasivanon V, Prarinyanuparp V, et al. Effect of single-dose albendazole and single-dose mebendazole on Necator americanus. Southeast Asian J Trop Med Public Health 1989;20:237-242
36. Wilmshurst JM, Robb SA. Can mebendazole cause lateralized occipital seizures? Eur J Paediatr Neurol 1998;2:323-324
37. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988;34:315-317 (Pubitemid 18103381)
38. Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705-708 (Pubitemid 16018950)
39. Redondo PA, Alvarez AI, Garcia JL, et al. Presystemic metabolism of albendazole: experimental evidence of an efflux process of albendazole sulfoxide to intestinal lumen. Drug Metab Dispos 1999;27:736-740 (Pubitemid 29252450)
40. Morris DL, Chinnery JB, Georgiou G, et al. Penetration of albendazole sulphoxide into hydatid cysts. Gut 1987;28:75-80 (Pubitemid 17231551)
41. Moskopp D, Lotterer E. Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst. Neurosurg Rev 1993;16:35-37 (Pubitemid 23132170)
42. Venkatesan P. Albendazole. J Antimicrob Chemother 1998;41:145-147
43. Schipper HG, Koopmans RP, Nagy J, et al. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg 2000;63:270-273 (Pubitemid 32537562)
44. Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 1997;19:51-5 •• Dexamethasone decreases the elimination rate of the active metabolite albendazole sulfoxide, which is clinically relevant in neurocysticercosis.
45. Sacko M, De Clercq D, Behnke JM, et al. Comparison of the efficacy of mebendazole, albendazole and pyrantel in treatment of human hookworm infections in the southern region of Mali, West Africa. Trans R Soc Trop Med Hyg 1999;93:195-203 (Pubitemid 29233862)
46. Heukelbach J, Feldmeier H. Epidemiological and clinical characteristics of hookworm-related cutaneous larva migrans. Lancet Infect Dis 2008;8:302-309 (Pubitemid 351615757)
47. Hochedez P, Caumes E. Hookworm-related cutaneous larva migrans. J Travel Med 2007;14:326-333 (Pubitemid 47460253)
48. Menard A, Dos SG, Dekumyoy P, et al. Imported cutaneous gnathostomiasis: report of five cases. Trans R Soc Trop Med Hyg 2003;97:200-202 (Pubitemid 37265634)
49. Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic strongyloidiasis. QJM 1993;86:191-195 (Pubitemid 23120814)
50. Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008;31:46-49 (Pubitemid 350236729)
51. Datry A, Hilmarsdottir I, Mayorga-Sagastume R, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 1994;88:344-345 (Pubitemid 24206464)
52. Saporito L, Scarlata F, Colomba C, et al. Human toxocariasis: a report of nine cases. Acta Paediatr 2008;97:1301-1302
53. Nabi F, Palaha HK, Sekhsaria D, Chiatale A. Capillaria hepatica infestation. Indian Pediatr 2007;44:781-782 (Pubitemid 350021508)
54. Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987;18:507-510 (Pubitemid 18109212)
55. Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992;86:418-421
56. Nontasut P, Claesson BA, Dekumyoy P, et al. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health 2005;36:650-652 (Pubitemid 41316788)
57. Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991;104:27-31
58. McKellar QA, Scott EW. The benzimidazole anthelmintic agents- a review. J Vet Pharmacol Ther 1990;13:223-247
59. Akkoc N, Kuruuzum Z, Akar S, et al. A large-scale outbreak of trichinellosis caused by Trichinella britovi in Turkey. Zoonoses Public Health. In press
60. Schellenberg RS, Tan BJ, Irvine JD, et al. An outbreak of trichinellosis due to consumption of bear meat infected with Trichinella nativa, in 2 northern Saskatchewan communities. J Infect Dis 2003;188:835-843 (Pubitemid 37176029)
61. Jongwutiwes S, Chantachum N, Kraivichian P, et al. First outbreak of human trichinellosis caused by Trichinella pseudospiralis. Clin Infect Dis 1998;26:111-115 (Pubitemid 28068163)
62. Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994;88:200-203 (Pubitemid 24139688)
63. Singh SP, Panda C, Rout N, Mishra AP. Anal albendazole application for pruritus ani in threadworm infestation. J Trop Pediatr 2005;51:386 (Pubitemid 43118427)
64. Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003;37:1073-1083 (Pubitemid 37323662)
65. Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005;9:69-76 • A review of surgical and non-surgical treatment options for cystic hepatic echinococcosis.
66. Caglar R, Yuzbasioglu MF, Bulbuloglu E, et al. In vitro effectiveness of different chemical agents on scolices of hydatid cyst. J Invest Surg 2008;21:71-75
67. Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 1993;342:1269-1272
68. Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 1993;35:565-574 (Pubitemid 23180994)
69. Ntusi NA, Horsfall C. Severe disseminated hydatid disease successfully treated medically with prolonged administration of albendazole. QJM 2008;101:745-746
70. Aggarwal P, Wali JP. Albendazole in the treatment of pulmonary echinococcosis. Thorax 1991;46:599-600
71. Nahmias J, Goldsmith R, Soibelman M, et al. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994;88:295-304 (Pubitemid 24231922)
72. Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992;15:234-249
73. Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994;19:735-742 (Pubitemid 24066907)
74. Wen H, Zou PF, Yang WG, et al. Albendazole chemotherapy for human cystic and alveolar echinococcosis in north-western China. Trans R Soc Trop Med Hyg 1994;88:340-343
75. Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-56 • General recommendations for treatment of neurocysticercosis.
76. Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008;79:1050-1055
77. Garg RK. Treatment of neurocysticercosis: is it beneficial? Expert Rev Anti Infect Ther 2008;6:435-440
78. Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2(3):e194 (Pubitemid 352002945)
79. Garcia HH. Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel? Expert Rev Anti Infect Ther 2008;6:295-298
80. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005;6:179-200 (Pubitemid 40305333)
81. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999;15:382-386 (Pubitemid 29392920)
82. Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997;350:480-484
83. Beach MJ, Streit TG, Addiss DG, et al. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg 1999;60:479-86 • Combined albendazole and ivermectin is more efficacious for intestinal helminths and W. bancrofti infections in children than either drug alone.
84. Critchley J, Addiss D, Gamble C, et al. International Filariasis Review Group. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev 2005;19:CD003753
85. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999;29:680-682 (Pubitemid 29439973)
86. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000;121(Suppl):S113-32 • A comprehensive review of albendazole with data on efficacy and safety.
87. Bagheri H, Simiand E, Montastruc JL, Magnaval JF. Adverse drug reactions to anthelmintics. Ann Pharmacother 2004;38:383-388 (Pubitemid 38235325)
88. Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998;45:601-604 (Pubitemid 28270917)
89. El Tantawy WH, Salem HF, Mohammed Safwat NA. Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm World Sci 2007;29:190-198 (Pubitemid 46872981)
90. Keiser J, El Ela NA, El Komy E, et al. Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. Am J Trop Med Hyg 2006;75:287-291 (Pubitemid 46941346)
91. Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg 2008;102:314-8 • A good overview of the potentially lethal Strongyloides hyperinfection syndrome, one of the helminth infections which deserves more attention.
92. Brennan GP, Fairweather I, Trudgett A, et al. Understanding triclabendazole resistance. Exp Mol Pathol 2007;82:104-9 • The alarming spread of triclabendazole-resistance in fascioliasis in animals is a warning that infections with resistant liver flukes might appear in humans.
93. Aksoy DY, Kerimoglu U, Oto A, et al. Infection with Fasciola hepatica. Clin Microbiol Infect 2005;11:859-861 (Pubitemid 41535920)
94. Jave OJA, Alban OM, Sagastegui PC, Soriano YS. Treatment of human hepatic fasciolaisis with triclabendazole [Article in Spanish]. Rev Gastroenterol Peru 1999;19:216-220
95. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol 2005;79:227-234 (Pubitemid 41192536)
96. Mottier L, Alvarez L, Fairweather I, Lanusse C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. J Parasitol 2006;92:1355-1360 (Pubitemid 46254499)
97. Calvopina M, Guderian RH, Paredes W, et al. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg 1998;92:566-569
98. Keiser J, Engels D, Büscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005;14:1513-26 • This review of triclabendazole includes an overview of data in laboratory animals and clinical trials in humans infected with F. hepatica or Paragonimus sp.
99. Gao J, Liu Y, Wang X, Hu P. Triclabendazole in the treatment of Paragonimiasis skrjabini. Chin Med J (Engl) 2003;116:1683-1686 (Pubitemid 38008237)
100. el Morshedy H, Farghaly A, Sharaf S, et al. Triclabendazole in the treatment of human fascioliasis: a community-based study. East Mediterr Health J 1999;5:888-894
101. Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane Database Syst Rev 2007;CD003758 (Pubitemid 351820439)
102. Awadzi K, Adjepon-Yamoah KK, Edwards G, et al. The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis. Br J Clin Pharmacol 1986;21:669-676 (Pubitemid 16004855)
103. Peixoto CA, Rocha A, Aguiar-Santos A, Florencio MS. The effects of diethylcarbamazine on the ultrastructure of microfilariae of Wuchereria bancrofti in vivo and in vitro. Parasitol Res 2004;92:513-517
104. Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 2005;5:514-523
105. Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002;185:805-811 (Pubitemid 34226208)
106. Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001;358:1873-1875
107. Dreyer G, Addiss D, Noroes J. Does longevity of adult Wuchereria bancrofti increase with decreasing intensity of parasite transmission? Insights from clinical observations. Trans R Soc Trop Med Hyg 2005;99:883-892 (Pubitemid 41511448)
108. Carme B, Boulesteix J, Boutes H, Puruehnce MF. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 1991;44:684-690
109. Bouree P, Duedari N, Bisaro F, Norol F. Value of filariopheresis in the treatment of Loa loa filariasis. Pathol Biol (Paris) 1993;41:410-414
110. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol 2001;75:299-305 (Pubitemid 34003174)
111. Finsterer J, Auer H. Neurotoxocarosis. Rev Inst Med Trop Sao Paulo 2007;49:279-287
112. Omura S. Ivermectin:25 years and still going strong. Int J Antimicrob Agents 2008;31:91-8 •• Description of the history of ivermectin, "the miracle drug", by one of the original researchers.
113. Omura S, Crump A. The life and times of ivermectin - a success story. Nat Rev Microbiol 2004;2:984-989 (Pubitemid 39562537)
114. Ikeda T. Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Nippon Yakurigaku Zasshi 2003;122:527-538 (Pubitemid 38019945)
115. Zeng Z, Andrew NW, Arison BH, et al. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998;28:313-321 (Pubitemid 28138966)
116. Basanez MG, Pion SD, Boakes E, et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:310-322 (Pubitemid 351615758)
117. Thylefors B, Alleman MM, Twum-Danso NA. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. Trop Med Int Health 2008;13:689-696 (Pubitemid 351561611)
118. Martin-Prevel Y, Cosnefroy JY, Tshipamba P, et al. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg 1993;48:186-192 (Pubitemid 23083733)
119. Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003;2(Suppl 1):S7
120. Nutman TB, Nash TE, Ottesen EA. Ivermectin in the successful treatment of a patient with Mansonella ozzardi infection. J Infect Dis 1987;156:662-665 (Pubitemid 17154681)
121. Van den Enden E, Van Gompel A, Van der SP, et al. Treatment failure of a single high dose of ivermectin for Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 1993;87:90 (Pubitemid 23093076)
122. Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989;40:304-309 (Pubitemid 19111614)
123. Van den Enden E, Stevens A, Van Gompel A. Treatment of cutaneous larva migrans. N Engl J Med 1998;339:1246-1247
124. Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-1079 (Pubitemid 24303229)
125. Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002;8:94-98 (Pubitemid 34456587)
126. Zaha O, Hirata T, Uchima N, et al. Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 2004;10:348-351 (Pubitemid 40142826)
127. Torres JR, Isturiz R, Murillo J, et al. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis 1993;17:900-902 (Pubitemid 23321915)
128. Kraivichian K, Nuchprayoon S, Sitichalernchai P, et al. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg 2004;71:623-628 (Pubitemid 39601162)
129. Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003;68:453-455 (Pubitemid 38230646)
130. Strong M, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev 2007;CD000320
131. Foucault C, Ranque S, Badiaga S, et al. Oral ivermectin in the treatment of body lice. J Infect Dis 2006;193:474-476 (Pubitemid 43122350)
132. Jones KN, English JC III. Review of common therapeutic options in the United States for the treatment of pediculosis capitis. Clin Infect Dis 2003;36:1355-1361 (Pubitemid 36702867)
133. Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985;313:133-138 (Pubitemid 15047454)
134. Pacque M, Munoz B, Poetschke G, et al. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990;336:1486-1489
135. Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003;2(Suppl 1):S3
136. Twum-Danso NA. Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded? Ann Trop Med Parasitol 2004;98:99-114
137. Eng JK, Prichard RK. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated and ivermectin-treated patients. Mol Biochem Parasitol 2005;142:193-202 (Pubitemid 40835911)
138. Prichard RK, Roulet A. ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 2007;134:1123-1132 (Pubitemid 47026662)
139. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004;98:231-49 •• An important study of ivermectin-resistance in Onchocerca volvulus.
140. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007;369:2021-2029
141. Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998;34:503-515 (Pubitemid 28271899)
142. Castro N, Gonzalez-Esquivel DF, Lopez M, Jung H. Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel. Rev Invest Clin 2003;55:655-661 (Pubitemid 38324826)
143. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006;368:1106-18 •• An excellent in-depth review of schistosomiasis.
144. Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res 2003;90(Supp 1):S3-9
145. Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006;52:339-345
146. van Lieshout L, Stelma FF, Guisse F, et al. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 1999;61:760-765
147. Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999;60:932-935 (Pubitemid 29296217)
148. Tsai MH, Marx KA, Ismail MM, Tao L. Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs. J Parasitol 2000;86:146-149 (Pubitemid 30126487)
149. Kieu TL, Bronshtein AM, Sabgaida TP. [Clonorchiasis in the People's Republic of Vietnam. 2. The clinico-parasitological examination of a focus and a trial of prazinquantel treatment]. Med Parazitol (Mosk) 1992;7-11
150. Choi MH, Chang BC, Lee SJ, et al. Therapeutic evaluation of sustained-releasing praziquantel (SRP) for clonorchiasis: phase 1 and 2 clinical studies. Korean J Parasitol 2006;44:361-366
151. Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004;5:1711-26 •• An excellent and systematic review covering the food-borne trematodes.
152. Pretell EJ, Garcia HH, Gilman RH, et al. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg 2001;103:175-177 (Pubitemid 32816283)
153. Adam I, Elwasila ET, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004;98:540-543
154. Olds GR. Administration of praziquantel to pregnant and lactating women. Acta Trop 2003;86:185-195 (Pubitemid 36561367)
155. White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004;2:43-49
156. Nitazoxanide (Alinia)- new anti-protozoal agent. Med Lett Drugs Ther 2003;45:29-31
157. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67:1947-67 • A good introduction and review of this new drug. (Pubitemid 47347408)
158. Hemphill A, Mueller J, Esposito M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 2006;7:953-964
159. Juan JO, Lopez CN, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002;96:193-196 (Pubitemid 34846567)
160. Chero JC, Saito M, Bustos JA, et al. Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans R Soc Trop Med Hyg 2007;101:203-205 (Pubitemid 44848175)
161. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 1984;33:511-512 (Pubitemid 14075656)
162. Lateef M, Zargar SA, Khan AR, et al. Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int J Infect Dis 2008;12:80-82 (Pubitemid 350299228)
163. Palomares-Alonso F, Piliado JC, Palencia G, et al. Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts. J Antimicrob Chemother 2007;59:212-218 (Pubitemid 47072059)
164. Reuter S, Manfras B, Merkle M, et al. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 2006;50:2966-2970
165. Favennec L, Jave OJ, Gargala G, et al. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003;17:265-270 (Pubitemid 36174258)
166. Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005;60:245-84 • An overview of current knowledge of the intracellular bacterial symbiont of certain filariae. The endosymbiont is essential for normal parasite development and fertility,
167. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008;197:295-311
168. Hoerauf A, Marfo-Debrekyei Y, Buttner M, et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol Res 2008;103:279-286
169. Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 2008;103:1303-1309
170. Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005;365:2116-2121 (Pubitemid 40826969)
171. Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006;42:1081-1089
172. Xiao S, Tanner M, N'Goran EK, et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 2002;82:175-81 • Artemether integrated with other control strategies has potential for reducing the burden of schistosomiasis. (Pubitemid 34518567)
173. Li YS, Chen HG, He HB, et al. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop 2005;96:184-190
174. Adam I, Elhardello OA, Elhadi MO, et al. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol 2008;102:39-44
175. Boulanger D, Dieng Y, Cisse B, et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg 2007;101:113-116
176. Borrmann S, Szlezák N, Faucher JF, et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis 2001;184:1363-1366 (Pubitemid 33055588)
177. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007;8:105-116 (Pubitemid 46438464)
178. Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008;78:388-392 (Pubitemid 351845185)
179. Keiser J, Morson G. Fasciola hepatica: tegumental alterations in adult flukes following in vitro and in vivo administration of artesunate and artemether. Exp Parasitol 2008;118:228-237
180. Xiao SH, Wu HM, Tanner M, et al. Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop 2005;94:1-14 • A review of a new Chinese anthelminthic for patients with ancylostomiasis, ascariasis and enterobiasis.
181. Zhang JH, Xiao SH, Wu ZX, et al. [Tribendimidine enteric coated tablet in treatment of 1,292 cases with intestinal nematode infection- a phase IV clinical trial]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2008;26:6-9
182. Keiser J, Xiao SH, Chollet J, et al. Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini. Antimicrob Agents Chemother 2007;51:1096-1098 (Pubitemid 46355303)
183. Xue J, Utzinger J, Zhang YN, et al. Artemether and tribendimidine lack activity in experimental treatment of Paragonimus westermani in the dog. Parasitol Res 2008;102:537-540
184. Xiao SH, Jian X, Tanner M, et al. Artemether, artesunate, praziquantel and tribendimidine administered singly at different dosages against Clonorchis sinensis: a comparative in vivo study. Acta Trop 2008;106:54-59
185. Keiser J, Utzinger J, Xiao SH, et al. Opisthorchis viverrini: efficacy and tegumental alterations following administration of tribendimidine in vivo and in vitro. Parasitol Res 2008;102:771-776
186. Keiser J, Thiemann K, Endriss Y, Utzinger J. Strongyloides ratti: In Vitro and In Vivo Activity of Tribendimidine. PLoS Negl Trop Dis 2008;2(1):e136
187. Steinmann P, Zhou XN, Du ZW, et al. Tribendimine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: Open-label randomized trial. PLoS Negl Trop Dis 2008;2(10): e322
188. Sheir Z, Nasr AA, Massoud A, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 2001;65:700-704 (Pubitemid 34049459)
189. Barakat R, Elmorshedy H, Fenwick A. Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. Am J Trop Med Hyg 2005;73:365-367 (Pubitemid 41278714)
190. Botros S, Sayed H, El Dusoki H, et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am J Trop Med Hyg 2005;72:119-123 (Pubitemid 41278892)
191. Abo-Madyan AA, Morsy TA, Motawea SM, Morsy AT. Clinical trial of Mirazid in treatment of human fascioliasis, Ezbet El-Bakly (Tamyia Center) Al-Fayoum Governorate. J Egypt Soc Parasitol 2004;34:807-818
192. Harder A, Holden-Dye L, Walker R, Wunderlich F. Mechanisms of action of emodepside. Parasitol Res 2005;97(Suppl 1):S1-S10 (Pubitemid 41446641)
193. Scherkenbeck J, Jeschke P, Harder A. PF1022A and related cyclodepsipeptides - a novel class of anthelmintics. Curr Top Med Chem 2002;2:759-777
194. Harder A, Schmitt-Wrede HP, Krucken J, et al. Cyclooctadepsipeptides- an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents 2003;22:318-331 (Pubitemid 37103217)
195. Guest M, Bull K, Walker RJ, et al. The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int J Parasitol 2007;37:1577-1588 (Pubitemid 47542465)
196. Tagboto SK, Townson S. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo. Ann Trop Med Parasitol 1996;90:497-505
197. Saeger B, Schmitt-Wrede HP, Dehnhardt M, et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J 2001;15:1332-1334
198. Mentz MB, Graeff-Teixeira C. Drug trials for treatment of human angiostrongyliasis. Rev Inst Med Trop Sao Paulo 2003;45:179-184 (Pubitemid 37107952)
199. Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003;43:1108-1115 (Pubitemid 37174442)
200. Keiser J, Xiao SH, Dong Y, et al. Clonorchicidal properties of the synthetic trioxolane OZ78. J Parasitol 2007;93:1208-1213 (Pubitemid 350211676)
201. Keiser J, Utzinger J, Vennerstrom JL, et al. Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans R Soc Trop Med Hyg 2007;101:1219-1222 (Pubitemid 350047385)
202. Keiser J, Utzinger J. Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 2007;23:555-62 • Artemisinins are well-known for their antimalarial activity, but also might have a role in several helminth infections.
203. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007;20:605-612 (Pubitemid 350059520)
204. Xiao SH, Keiser J, Chollet J, et al. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 2007;51:1440-1445
205. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007;11:433-439 (Pubitemid 47302844)
206. Omura S, Miyadera H, Ui H, et al. An anthelmintic compound, nafuredin, shows selective inhibition of complex I in helminth mitochondria. Proc Natl Acad Sci USA 2001;98:60-62 (Pubitemid 32095863)
207. Cioli D, Valle C, Angelucci F, Miele AE. Will new antischistosomal drugs finally emerge? Trends Parasitol 2008;24:379-382
208. Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008;14:407-412
209. Behm CA, Bendig MM, McCarter JP, Sluder AE. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol 2005;21:97-100
210. Rey P, Debonne JM. Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults. Med Trop (Mars) 2006;66:324-328
211. Lawrence D. What's in a name? Drug resistance in helminth parasites. Lancet Infect Dis 2008;8:536
212. Bennett A, Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol Today 2000;16:71-4 •• A critical look at published cure rates and egg reduction rates of ascariasis, trichuriasis and hookworm disease.
213. Waghorn TS, Leathwick DM, Miller CM, Atkinson DS. Brave or gullible: testing the concept that leaving susceptible parasites in refugia will slow the development of anthelmintic resistance. NZ Vet J 2008;56:158-63 • Investigation of the concept of ecological refugia in veterinary medicine. The finding that a reservoir of unselected parasites slows development of anthelminthic resistance might influence treatment strategies in human medicine.
214. Hotez PJ, Bethony JM, Oliveira SC, et al. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 2008;7:745-752
215. Oliveira SC, Fonseca CT, Cardoso FC, et al. Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop 2008;108:256-262
216. Brutus L, Watier L, Hanitrasoamampionona V, et al. Confirmation of the protective effect of Ascaris lumbricoides on Plasmodium falciparum infection: results of a randomized trial in Madagascar. Am J Trop Med Hyg 2007;77:1091-1095 (Pubitemid 351837799)
217. Reddy A, Fried B. Atopic disorders and parasitic infections. Adv Parasitol 2008;66:149-191 (Pubitemid 351672130)
218. van Riet E. Protection from skin test reactivity by helminth infections: Trichuris trichiura induces protection in the long term. Clin Exp Allergy 2008;38:1702-1704
219. Ruyssers NE, De Winter BY, De Man JG, et al. Worms and the treatment of inflammatory bowel disease: are molecules the answer? Clin Dev Immunol 2008;2008:567314